India has failed to set up a mechanism that "adequately preservesnovelty and priority in respect of applications for product patents for pharmaceuticals and agricultural chemical inventions" during the transitional period it was accorded as a developing country under World Trade Organization rules.
In addition, India has failed to publish and notify adequately information about any such mechanism, according to the interim ruling of the WTO dispute-settlement panel, which also found that the country had not set up a system to grant exclusive marketing rights.
According to Dow Jones, the panel recommended that India brings its patent regime in line with its obligations, and that it takes into account the interests of those who would have filed an application had a proper mechanism been maintained and of those who filed applications under administrative practices now in place.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze